Current perspectives on the use of intravenous immunoglobulin

Advances in Internal Medicine

Volumn 41, Issue , 1996, Pages 641-680

  Dickler, Howard B ^a   Gelfand, Erwin W ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

HUMAN; IMMUNOPATHOLOGY; INFECTION; REVIEW;

HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION;

EID: 0030339839     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Imbach P, Barandum S, d'Apuzzo V, et al: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1230, 1981.
2. Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Eng] J Med 325:110-117, 1991.
3. Chemini J, Peppard E, Emanuel D: Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: An in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant 2:395-402, 1987.
4. Bjoro K, Froland SS, Yuru Z, et al: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Eng] J Med 331:1607-1611, 1994.
5. Schiff R: Transmission of viral infections through intravenous immune globulin. N Engl J Med 331:1649-1650, 1994.
6. Umetsu DT, Ambrosino DM, Quinti I, et al: Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Eng] J Med 313:1247-1251, 1985.
7. Scott MG, Shackelford PG, Briles DE, et al: Human IgG subclasses and relation to carbohydrate antigen immunocompetence. Diagn Clin Immuno] 5:241-248, 1988.
8. Ferrante A: IgG subclass deficiency: Fact or fiction. Pediatr Infect Dis J 9(suppl):51-63,1990.
9. Yount WJ, Kunkel HJ, Litwin SD: Studies of the Vi (y2c) subgroup of /-globulin. A relationship between the concentration and genetic type among normal individuals. J Exp Med 125:177-190, 1967.
10. Buckley RH: Plasma therapy in immunodeficiency diseases. Am J Dis Child 124:376-381, 1972.
11. Ammann A, Ashman RF, Buckley RH, et al: Use of intravenous gammaglobulins in antibody immunodeficiency: Results of a multicenter controlled trial. CJin Immunol Immunopatho] 22:60-67, 1982.
12. Sorenson RU, Polmar SH: Efficacy and safety of high dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med 76(suppl 3A):83-90, 1984.
13. Montanaro A, Pirofsky B: Prolonged interval high dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 76(suppl 3A):62-72, 1984.
14. Roifman CM, Lederman HM, Lavi S, et al: Benefit of intravenous IgG replacement in hypogammaglobulinemia patients with chronic sinopulmonary disease. Am J Med 79:171-174, 1985.
15. Roifman CM, Levison H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1:1075-1078, 1987.
16. Bernatowska E, Madalinski K, Janowicz W, et al: Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. CJin ImmunoJ Immunopathol 43:153-162, 1987.
17. Liese JG, Wintergerst U, Tympner KD, et al: High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis ChiJd 146:335-339, 1992.
18. Gardulf A, Hammarstrom L, Smith CIE: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162-166, 1991.
19. Matheson DS, Clarkson TW, Gelfand EW: Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin. J Pediatr 97:153-155, 1980.
20. Hetherington SV, Giebink GS: Opsonic activity of immunoglobulin prepared for intravenous use. J Lab Clin Med 104:977-986, 1984.
21. Van Furth R, Leijh PCJ, Klein F: Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. J Infect Dis 149:511-517, 1984.
22. Van Furth R, Braat ACP, Leijh PCJ, et al: Opsonic and physicochemical characteristics of intravenous immunoglobulin preparations. Vox Sang 53:70-75, 1987.
23. Siber GR, Snydman DR: Use of immune globulins in the prevention and treatment of infections. Curr Clin Top Infect Dis 12:208-256,1992.
24. Roifman CM, Rao CP, Lederman HM, et al: Increased susceptibility to mycoplasma infection in patients with hypogammaglobulinemia. Am JMed 80:590-594, 1986.
25. Gelfand EW: Unique susceptibility of patients with antibody deficiency to mycoplasma infection. CJin Infect Dis 17(suppl]:5250- 5253,1993.
26. Takei S, Arora YK, Walker SM: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococci toxin superantigens. J Clin Invest 91:602-607, 1993.
27. Miescher PA, Jaffe ER (eds): Current approaches to the prevention and treatment of cytomegalovirus disease after bone marrow transplantation. Semin Hematol, vol 27, no 2, suppl 1, 1990.
28. Miescher PA, Jaffe ER (eds): IVIG: Current role in bone marrow transplant, malignancy and immune hématologie disorders. Semin Hematol, vol 29, no 3, suppl 2, 1992.
29. Bass EB, Power NR, Goodman SN, et al: Efficacy of immune globulin in preventing complications of bone marrow transplantation: A metaanalysis. Bone Marrow Transplant 12:273-282, 1993.
30. Aulitsky WE, Tilg H, Niederwasser D, et al: Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. J Infect Dis 158:488-489, 1988.
31. Verdonck LF, deGast GC, Dekker AW, et al: Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 4:187-189, 1989.
32. Dunn DL, Gillingham KJ, Kramer MA, et al: A prospective randomized study of acylovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 57:876-884, 1994.
33. Sullivan KM: Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 4(suppl l):42-93, 1986.
34. Sullivan KM, Kopecky KJ, Jocom J, et al: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705-712, 1990.
35. Witherspoon RP, Storb R, Ochs HD, et al: Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time post-transplantation, the presence or absence of chronic graftversus-host disease and anti-thymocyte globulin treatment. Blood 58:360-368, 1981.
36. Perreault C, Giasson NY, Gyger M: Serum immunoglobulin levels following allogeneic marrow transplantation. Blut 51:137-146, 1985.
37. Copelan EA, Avalos BR, Kapoot N, et al: Alternate applications of immunoglobulin following bone marrow transplantation. Semin Hematol 29(suppl 2):96-99, 1992.
38. Sullivan KM: Intravenous immune globulin prophylaxis in recipients of a marrow transplant. J Allergy Clin Immunol 84:632-639, 1989.
39. Winston DJ, Schiffman G, Wang DC, et al: Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 91:835-841, 1979.
40. Sheridan JF, Tutschka PJ, Sednak DD, et al: Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 75:1583-1586, 1990.
41. Gugliemo BJ, Wong-Beringer A, Linker CA: Immune globulin therapy in allogeneic bone marrow transplant: A critical review. Bone Marrow Transplant 13:499-510, 1994.
42. Wolff SN, Fay JW, Herzig RH, et al: High-dose intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 118:937-942, 1993.
43. Hansen MM: Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 18(suppl):l186, 1973.
44. Jim RT, Reinhard EH: Agammaglobulinemia in chronic lymphocytic leukemia. Ann Intern Med 44:790-796, 1956.
45. Miller DG: Patterns of immunological deficiency in lymphomas and leukemias. Ann Intern Med 57:703-716, 1962.
46. Fairlay GH, Scott RB: Hypogammaglobulinemia in chronic lymphocytic leukemia. BMJ 4:920-924, 1961.
47. Besä EC: Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 76:209-218,1984.
48. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 319:902-907, 1988.
49. Jurlander J, Hartmann GC, Hansen MM: Treatment of hypogamma- globulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. EurJHaematoI 53:114-118, 1994.
50. Sklenar I, Schiffman G, Jonsson V, et al: Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 50:466-477, 1993.
51. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81-86, 1991.
52. Twomey JH: Infections complicating multiple myeloma and chronic lymphocytic leukaemia. Arch Intern Med 132:562-565, 1973.
53. Hargreaves R, Griffiths H, Faux J, et al: Infection and immunological responses in myeloma. Blood 76(suppl):352-362, 1991.
54. Espersen F, Birgens HS, Hertz JB, et al: Current patterns of bacterial infection in myelomatosis. Scand J Infect Dis 16:169-73, 1984.
55. Jacobson DR, Zolla-Pazner S: Infection and immunosuppression in myeloma. Semin Oncol 13:282-290, 1986.
56. Chapel HM, Lee M, Hargreaves R, et al: Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateauphase multiple myeloma. Lancet 343:1059-1063, 1994.
57. Bernstein LJ, Krieger BZ, Novick B, et al: Bacterial infections in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis 4:472-475, 1985.
58. Zolla-Pazner S: Immunologie abnormalities in infection with the human immunodeficiency virus. Lab Med 17:685-689, 1986.
59. Cavelli TA, Rubinstein A: Intravenous gammaglobulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis 5:5207-5210, 1986.
60. Oleski JM, Connor EM, Bohila R, et al: Treatment of immunodeficiency virus antibody positive children with intravenous immunoglobulin. Vox Sang 52:162-175, 1987.
61. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group: Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 325:73-80, 1991.
62. Spector A, Gelber RD, McGrath N, et al: Controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 331:1181-1187, 1994.
63. Pahwa S: Intravenous immune globulin in patients with acquired immune deficiency syndrome. J Allergy Ch'n Immunol 84:625-631, 1989.
64. Oksenhendler E, Bierling JP, Rabian C, et al: Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. Br J Haemato] 66:491-495, 1987.
65. Jahnke L, Appelbaum S, Sherman LA, et al: An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion 34:759-764, 1994.
66. Goldmann DA: Prevention and management of neonatal infections. Infect Dis Clin North Am 3:779-813, 1989.
67. Baker CJ, Melish ME, Hall RT, et al: Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Eng] J Med 327:213-219, 1992.
68. Fanaroff AA, Korones SB, Wright LL, et al: A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-lowbirth-weight infants. N Eng] J Med 331:1107-1113, 1994.
69. Schreiber JR, Berger M: Intravenous immune globulin therapy for sepsis in premature neonates. J Pediatr 121:401-404, 1992.
70. Schreiber JR, Basker G, Priehs G, et al: Deleterious effect of immune globulin in the treatment of H. influenzae b infection in infant rats (abstract). Pediatr Res 21:334, 1987.
71. Kim K, Hong J: High dose of intravenous immunoglobulin (IVIG) may impair therapeutic benefit of penicillin (P) against experimental group B streptococcal (GBS) bacteremia and meningitis (abstract). Pediatr Res 21:417, 1987.
72. Weisman LE, Stoll BJ, Kueser TJ, et al: Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr 121:434-443, 1992.
73. Groothuis JR, Simoes EAF, Levin MJ, et al: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Eng] J Med 329:1524-1530, 1993.
74. Santosham M, Reid R, Ambrosino DM, et al: Prevention of Haemophilus influenzae type B infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 317:923-929, 1987.
75. Shurin PA, Rehmus JM, Johnson CE, et al: Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 123:801-810, 1993.
76. Ziegler EC, McCutchan JA, Fierer J, et al: Treatment of gram negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Eng] J Med 307:1225-1230, 1982.
77. Baumgartner JD, Glauser MP, McCutchan JA, et al: Prevention of gramnegative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59-63, 1985.
78. Calandra T, Glauser MP, Schellekens J, et al: Treatment of gramnegative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158:312-319, 1988.
79. The Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of post-surgical infection. N Engl J Med 327:234-240, 1992.
80. Gooding AM, Bastian JF, Peterson BM, et al: Safety and efficacy of intravenous immunoglobulin prophylaxis in pédiatrie head trauma patients: A double-blind controlled trial. J Grit Care 8:212-216, 1993.
81. Glinz W, Grob PJ, Nydegger UE, et al: Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following trauma. Intensive Care Med 11:288-294, 1985.
82. Waymack JP, Jenkins ME, Alexander JW, et al: A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. Burns 15:71-76, 1989.
83. Kelton JG, Gibbons S: Autoimmune platelet destruction: Idiopathic thrombocytopenic purpura. Semin Thromb Hemost 8:83-104, 1982.
84. McMillan R, Tani P, Millard F, et al: Platelet-associated and plasma anti-glycoprotein auto antibodies in chronic ITP. BJood 70:1040-1045, 1987.
85. Beardsley DS: Platelet abnormalities in infancy and childhood, in Nathan DG, Oski FA (eds): Hematology of Infancy and Childhood, vol 2, ed 4. Philadelphia, WB Saunders, 1993, pp 1561-1604.
86. McMillan R: Chronic idiopathic thrombocytopenic purpura. N Engl J Med 304:1135-1147, 1981.
87. Imbach P, Berchtold W, Hirt A, et al: Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2:464-468, 1985.
88. Blanchette VS, Luke B, Andrew M, et al: A prospective randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123:989-995, 1993.
89. Blanchette V, Imbach P, Andrew M, et al: Randomized trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344:703-707, 1994.
90. Imholz B, Imbach P, Baumgartner C, et al: Intravenous immunoglobulin (i.v. IgGJ for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: A prospective multicenter study. Blut 56:63-68, 1988.
91. Jacobs P, Wood L, Novitzky N: Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: A prospective randomized clinical trial. Am J Med 97:55-59, 1994.
92. Godeau B, Lesage S, Divine M, et al: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. BJood 82:1415-1421, 1993.
93. Bussel JB, Pham LC, Aledorf L, et al: Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 72:121-127, 1988.
94. Ballin A, Andrew M, Ling E, et al: High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia. J Pediatr 112:789-792, 1988.
95. Fehr J, Hof mann V, Kappeier V: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N EngJ J Med 306:1254-1258, 1982.
96. Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fey receptor distribution and structure. Proc Nat Acad Sei U S A 79:3275-3279,1982.
97. Clarkson SB, Bussel JB, Kimberly RP, et al: Treatment of refractory immune thrombocytopenic purpura with an anti-Fc-y-receptor antibody. N EngJ J Med 314:1236-1239, 1986.
98. Debré M, Bonnet M-C, Fridman W-H, et al: Infusion of Fc-y fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342:945-949, 1993.
99. Kicker T, Braine HG, Piantadosis S, et al: A randomized, placebocontrolled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 75:313-316, 1990.
100. Tankersley DL: Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 139:159-172,1994.
101. Basta M, Langlois PF, Marques M, et al: High dose intravenous immunoglobulin modified complement-mediated in vivo clearance. Blood 74:326-333, 1989.
102. Berchtold P, Wenger M: Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 81:1246-1250, 1993.
103. Sultan Y, Kazatchkine MD, Maisonneuve P, et al: Anti-idiotypic suppression of autoantibodies to factor VIII (antihemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2:765-768, 1984.
104. Dietrich G, Rossi F, Kazatchkine MD: Modulation of autoimmune responses with normal polyspecific IgG for therapeutic use, in Melchers F, Albert ED, von Boehmer H, et al (eds): Progress in Immunology VII. Berlin, Springer-Verlag, 1989, pp 1221-1227.
105. Phillips NE, Parker DC: Fc-dependent inhibition of mouse B cell activation by whole anti-ji antibodies. J Immunol 130:602-606, 1983.
106. Über F, Dickler HB: Cooperativity between B lymphocyte membrane molecules: Independent ligand occupancy and cross-linking of antigen receptors and Fc-y receptors down-regulates B lymphocyte function. J Immunol 137:3124-3129, 1986.
107. Sundblad A, Marcos M-AR, Malanchere E, et al: Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev 139:125-158, 1994.
108. Abe Y, Horiuchi A, Miyaké M, et al: Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5-19, 1994.
109. Andersson V, Bjork L, Skansen-Saphir V, et al: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immuno] Rev 139:21-42, 1994.
110. Arend WP, Leung DYM: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 139:71-78, 1994.
111. Kawasaki T: Acute febrile mucocutaneous lymph node syndrome: Clinical observations of 50 cases. Jpn J Allergy 16:178-222, 1967.
112. Kato H, Ichinose E, Yoshioka F, et al: Fate of coronary aneurysms in Kawasaki disease: Serial coronary angiography and long term follow-up study. Am J Cardiol 49:1758-1766, 1982.
113. Furusho K, Nakano H, Shinomiya K, et al: High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2:1055-1058, 1984.
114. Newburger JW, Takahashi M, Burns JC, et al: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Eng] J Med 315:341-347, 1986.
115. Newburger JW, Takahashi M, Beiser AS, et al: A single infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Eng] J Med 324:1633-1639, 1991.
116. Meissner HC, Schlievert PM, Leung DYM: Mechanisms of immunoglobulin action: Observation on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 139:109-123, 1994.
117. Abe J, Kotzin BL, Meissner C, et al: Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 177:791-796, 1993.
118. Leung DYM, Meissner HC, Fulton DR, et al: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 342:1385-1388, 1993.
119. Arnason BW: Acute inflammatory demyelinating polyradiculoneuropathies, in Dyck PJ, Thomas PK, Lambert EH, et al (eds): Periphera] Neuropathy, ed 2. Philadelphia, WB Saunders, 1984, pp 2050-2100.
120. van der Mèche FGA, Schmitz PIM, Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Eng] JMed 326:1123-1129, 1992.
121. Dutch Guillain-Barre Study Group: Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neural 35:749-752, 1994.
122. Dalakas MC: Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 15:327351, 1992.
123. Dalakas MC, Ilia I, Dambrosia JM, et al: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000, 1993.
124. Cosi V, Lombard! M, Piccolo G, et al: Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neural Scand 84:81-84, 1991.
125. Flores G, Cunningham-Rundles C, Newland AC, et al: Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am J Hematol 44:237-242, 1993.
126. Achiron A, Pras E, Gilad R, et al: Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neural 49:1233-1236, 1992.
127. Azulay J-P, Blin O, Pouget J, et al: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with antiGM1 antibodies: A double-blind placebo-controlled study. Neurology 44:429-432, 1994.
128. Hilgartner MW, Bussel E: Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 83(suppl 4A):25-29, 1987.
129. Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N EngJ J Med 318:945-950, 1988.
130. Francioni C, Galeazzi M, Fioravanti A, et al: Long term I.V. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 12:163-168, 1994.
131. Tumiati B, Casoli P, Veneziani M, et al: High-dose immunoglobulin therapy as an immunomodulatory treatment in rheumatoid arthritis. Arthritis Rheum 35:1126-1133, 1992.
132. Silverman ED, Laxer RM, Greenwald M, et al: Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 33:1015-1022, 1990.
133. Cherin P, Herson S, Wechsler B, et al: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 91:162-168, 1991.
134. Godard W, Roujeau JC, Guillot B, et al: Bullous pemphigoid and intravenous immunoglobulin. Ann Intern Med 103:964-965, 1985.
135. Antonelli A, Saracino A, Albert! B, et al: High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta EndocrinoJ 126:13-23, 1992.
136. Levine DS, Fischer SH, Christies DL, et al: Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 87:91-100, 1992.
137. Drucker NA, Colan SD, Lewis AB, et al: y-Globulin treatment of acute myocarditis in the pédiatrie population. Circulation 89:252-257, 1994.
138. Mazer BD, Gelfand EW: An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy CJin Immunol 87:976-983, 1991.
139. Petersen PK, Shepard J, Macres M, et al: A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 89:554-560, 1990.
140. Lloyd A, Hickie I, Wakefield D, et al: A double-blind, placebocontrolled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 89:561-568, 1990.
141. van Doom PA, Brand A, Strengers PFW, et al: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind placebo-controlled, crossover study. Neurology 40:209-212, 1990.
142. Vermeulen M, van Doom PA, Brand A, et al: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36-39, 1993.
143. Heine O, Mueller-Eckhardt GM: Intravenous immunoglobulin in recurrent abortion. Ch'n Exp Immunol 97(suppl 1):39-42, 1994.
144. Coulam CB, Coulam CH: Update on immunotherapy for recurrent pregnancy loss. Am Jfleprod Immunol 27:124-127, 1992.
145. Centers for Disease Control and Prevention: Outbreak of hepatitis C associated with intravenous immunoglobulin adminstration-United States, October 1993-June 1994. MMWR 43:505-509,
146. IGIV transmission of hepatitis C. FDA Med Bull 24(no 2):3-4, 1994.
147. Bj0ro K, Froiand SS, Yun Z, et al: Hepatitis C infection in patients with primary hypogammaglobulinomia after treatment with contaminated immune globulin. N Engl J Med 331:1607-1611, 1994.
148. Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560-563, 1986.
149. Brox AG, Cournoyer D, Sternbach M, et al: Hemolytic anemia following intravenous gammaglobulin administration. Am J Med 82:633-635, 1987.
150. Kato E, Shindo S, Eto Y, et al: Administration of immune globulin associated with aseptic meningitis. JAMA 259:3269-3270, 1988.
151. Woodruff RK, Griff AP, Firkin FL, et al: Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulins in elderly patients. Lancet 2:217-218, 1986.
152. Rault R, Piraino B, Johnston JR, et al: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 36:83-86, 1991.